| Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study S Yusuf, S Hawken, S Ôunpuu, T Dans, A Avezum, F Lanas, M McQueen, ... The lancet 364 (9438), 937-952, 2004 | 17376 | 2004 |
| Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo … PM Ridker, JG MacFadyen, T Thuren, BM Everett, P Libby, RJ Glynn, ... The Lancet 390 (10105), 1833-1842, 2017 | 1222 | 2017 |
| Cholesterol lowering in intermediate-risk persons without cardiovascular disease S Yusuf, J Bosch, G Dagenais, J Zhu, D Xavier, L Liu, P Pais, ... New England Journal of Medicine 374 (21), 2021-2031, 2016 | 1023 | 2016 |
| Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial SS Anand, J Bosch, JW Eikelboom, SJ Connolly, R Diaz, P Widimsky, ... The Lancet 391 (10117), 219-229, 2018 | 946 | 2018 |
| Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled … PM Ridker, JG MacFadyen, BM Everett, P Libby, T Thuren, RJ Glynn, ... The Lancet 391 (10118), 319-328, 2018 | 819 | 2018 |
| Blood-pressure lowering in intermediate-risk persons without cardiovascular disease EM Lonn, J Bosch, P López-Jaramillo, J Zhu, L Liu, P Pais, R Diaz, ... New England Journal of Medicine 374 (21), 2009-2020, 2016 | 803 | 2016 |
| Blood-pressure and cholesterol lowering in persons without cardiovascular disease S Yusuf, E Lonn, P Pais, J Bosch, P Lopez-Jaramillo, J Zhu, D Xavier, ... New England Journal of Medicine 374 (21), 2032-2043, 2016 | 494 | 2016 |
| Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation S Yusuf, M Flather, J Pogue, D Hunt, J Varigos, L Piegas, A Avezum, ... The Lancet 352 (9127), 507-514, 1998 | 489 | 1998 |
| Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial SJ Connolly, JW Eikelboom, J Bosch, G Dagenais, L Dyal, F Lanas, ... The Lancet 391 (10117), 205-218, 2018 | 405 | 2018 |
| On behalf of the INTERHEART Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case … S Yusuf, S Hawken, S Ôunpuu, T Dans, A Avezum, F Lanas, M McQueen, ... Lancet 364 (9438), 937, 2004 | 178 | 2004 |
